THE M-BACOD COMBINATION CHEMOTHERAPY REGIMEN IN LARGE-CELL LYMPHOMA - ANALYSIS OF THE COMPLETED TRIAL AND COMPARISON WITH THE M-BACOD REGIMEN

被引:122
作者
SHIPP, MA
YEAP, BY
HARRINGTON, DP
KLATT, MM
PINKUS, GS
JOCHELSON, MS
ROSENTHAL, DS
SKARIN, AT
CANELLOS, GP
机构
[1] HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV BIOSTAT, BOSTON, MA 02115 USA
[2] HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT RADIOL, BOSTON, MA 02115 USA
[3] BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA
[4] HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA
关键词
D O I
10.1200/JCO.1990.8.1.84
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One hundred thirty-four assessable patients with stage II-IV large-cell lymphoma (LCL) were treated with the combination chemotherapy regimen methotrexate with leucovorin, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) between July 1981 and May 1986. The m-BACOD regimen substituted moderate-dose methotrexate (200 mg/m2 × 2) for the high-dose methotrexate used in the preceding M-BACOD regimen; all other drugs were administered as with m-BACOD. Eighty-two patients (61%) in the completed m-BACOD trial achieved a complete response (CR), With a median follow-up of 3.6 years, 62 patients (76%) continue in CR. Predicted survivals of 1, 3, and 5 years for the entire m-BACOD group are 80%, 63%, and 60%, respectively, with a 5-year disease-free survival (DPS) of 74% for the patients who achieve CR. The results obtained with m-BACOD are comparable with those obtained in the preceding M-BACOD trial, which now has a median follow-up of 8.0 years. The reduction in methotrexate dosage in m-BACOD patients was not associated with an increased incidence of CNS relapse. Long-term follow-up of the 215 M/m-BACOD patients indicates that the regimens are not associated with an increased incidence of secondary malignancy. Prolonged follow-up also indicates that advanced-stage patients have a persistent rate of late relapse of about 7.0% per year for years 2 to 5 of their follow-up and that stage II patients have an approximate 2.1 % per year rate of late relapse. Application of the previously described prognostic factor model to the 215 M/m-BACOD patients from the completed trials identifies a high-risk group of patients with a CR rate and predicted 5-year survival (38% and 24%, respectively) that are significantly worse than those of the group as a whole (65% and 57%, respectively). © 1990 by American Society of Clinical Oncology.
引用
收藏
页码:84 / 93
页数:10
相关论文
共 31 条
[11]  
FISHER RI, 1981, BLOOD, V58, P45
[12]  
HORM JW, 1984, NIH851837
[13]  
HSOKINS PJ, 1988, P AM ASSOC CANC RES, V7, P225
[14]   TUMOR BURDEN ASSESSMENT AND ITS IMPLICATION FOR A PROGNOSTIC MODEL IN ADVANCED DIFFUSE LARGE-CELL LYMPHOMA [J].
JAGANNATH, S ;
VELASQUEZ, WS ;
TUCKER, SL ;
FULLER, LM ;
MCLAUGHLIN, PW ;
MANNING, JT ;
NORTH, LB ;
CABANILLAS, FC .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :859-865
[15]  
KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI
[16]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[17]  
KIRKWOOD JM, 1981, CANCER, V47, P2412
[18]  
KLIMO P, 1987, SEMIN HEMATOL, V24, P26
[19]  
KWAK L, 1988, P AN M AM SOC CLIN, V7, P226
[20]   A 10-YEAR UPDATE OF CHOP-BLEO IN THE TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA [J].
LEE, R ;
CABANILLAS, F ;
BODEY, GP ;
FREIREICH, EJ .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (10) :1455-1461